Trial Profile
Post-Authorization Safety Study of Remsima® (Infliximab) in Rheumatoid Arthritis Patients in Jordan
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Mar 2020
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Acronyms PASSRRA
- Sponsors Hikma Pharmaceuticals
- 03 Mar 2020 Status changed from recruiting to completed.
- 22 Nov 2017 New trial record